Impact of new medications on the treatment of immune TTP
Abstract
Abstract The last decade has seen the introduction of 2 new licensed therapies for thrombotic thrombocytopenic purpura (TTP), caplacizumab and recombinant ADAMTS13 (rADAMTS13), for immune and congenital TTP (cTTP), respectively. They improve acute TTP outcomes, and reduce the need for plasma therapy, time to clinical response, and treatment burden. Future pathways need to replace plasma exchange in acute TTP and optimize/personalize rADAMTS13 in cTTP. Future emphasis should focus on additional monoclonals/treatments to tackle ADAMTS13 antibodies.
Article Details
Authors (3)
Marie Scully
1Department of Haematology, University College London Hospitals and Haematology Programme, National Institute for Health Research, University College London Hospitals, University College London Biomedical Research Centre, London, United Kingdom
Lara Howells
1University College London Hospital, London, United Kingdom
William A. Lester
3Department of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom